Background Image
Table of Contents Table of Contents
Previous Page  119 / 206 Next Page
Information
Show Menu
Previous Page 119 / 206 Next Page
Page Background

Notes to the financial statements

31 December 2014

Bursa Malaysia

Annual Report 2014

107

2. Significant accounting policies (cont’d.)

2.4 Summary of significant accounting policies (cont’d.)

(f) Impairment of financial assets

The Group and the Company assess at each financial year end whether there is any objective evidence that a financial asset is impaired.

(i) Loans and receivables and HTM investments

To determine whether there is objective evidence that an impairment loss on financial assets has been incurred, the Group and the Company

consider factors such as the probability of insolvency or significant financial difficulties of the debtor, default or significant delay in payments,

and delinquency in interest or principal payments and other financial reorganisation where observable data indicate that there is a measurable

decrease in the estimated future cash flows.

For certain categories of financial assets, such as trade receivables, assets that are assessed not to be impaired individually are subsequently

assessed for impairment on a collective basis based on similar risk characteristics. Objective evidence of impairment for a portfolio of receivables

could include the Group and the Company’s past experience of collecting payments, an increase in the number of delayed payments in the portfolio

past the average credit period and observable changes in national or local economic conditions that correlate with default on receivables.

If any such evidence exists, the amount of impairment loss is measured as the difference between the asset’s carrying amount and the present

value of estimated future cash flows discounted at the financial asset’s original effective interest rate. The impairment loss is recognised in profit

or loss.

The carrying amount of the financial asset is reduced by the impairment loss directly for all financial assets with the exception of trade and other

receivables, and staff loan receivables, where the carrying amount is reduced through the use of an allowance account. When a trade or other

receivable or staff loan receivable becomes uncollectible, it is written off against the allowance account.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be objectively related to an event occurring after

the impairment was recognised, the previously recognised impairment loss is reversed to the extent that the carrying amount of the asset does

not exceed its amortised cost at the reversal date. The amount of reversal is recognised in profit or loss.

(ii) AFS financial assets

To determine whether there is objective evidence that investment securities classified as AFS financial assets are impaired, the Group and the

Company consider factors such as significant and/or prolonged decline in fair value below cost, significant financial difficulties of the issuer or

obligor, and the disappearance of an active trading market.

If an AFS financial asset is impaired, an amount comprising the difference between its cost (net of any principal payment and amortisation or

accretion) and its current fair value, less any impairment loss previously recognised in profit or loss, is transferred from equity to profit or loss.

Impairment losses on AFS equity investments are not reversed in profit or loss in the subsequent periods. Increase in fair value, if any, subsequent

to impairment loss is recognised in other comprehensive income. For AFS debt investments, impairment losses are subsequently reversed

in profit or loss if an increase in the fair value of the investment can be objectively related to an event occurring after the recognition of the

impairment loss in profit or loss.

(g) Cash and cash equivalents

Cash and cash equivalents consist of cash at banks and on hand, and short-term deposits used by the Group and the Company in the management

of their short-term funding requirements.